·There are currently three beta-lactamase inhibitors on the market, tazobactam, sulbactam, and clavulanic acid each with an annual sales of close to or over a billion dollar.

· Morepen Laboratories announced 52 Drug Master Files (DMF) filings across ten European countries for six products. The filings are for cholesterol reducing drug Atorvastatin (Lipitor) for both the amorphous and the crystalline forms, antiasthmatic drug Desloratadine (Clarinex), antidiabetic drug Pioglitazone (Actos) and antibacterial drugs Sultamicillin Tosylate and Sultamicillin Base (Unasyn).